The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Status unconfirmed

Conditions studied: COVID-19 Vaccines

In brief

During the study, members of different online and offline communities will be followed post COVID-19 vaccination. Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either web surveys or personal communication, depending on study participant preference. Hypothesis to be tested: The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions, metabolism and microbiomes.

Key facts

Study ID

NCT04832932

Run by

Mebo Research, Inc.

People needed

2000

Starts

2021-01-05

Expected to finish

2025-01-05

Last updated by the study team

2024-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Individuals 18 or older at the time of consent
• Intention to vaccinate and of being available for entire study period

You may not qualify if…

• Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.

Where it is running

• MEBO Research, Inc — Miami, Florida, United States
• Kahite — Vonore, Tennessee, United States
• Gabashvili — Tbilisi, Georgia
• MEBO Research Africa — Kilifi, Kenya
• Mebo Research (Uk) — London, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.